Oncology Licensing Deal Benchmarks 2026

Phase 2 ADC (Median)

$2.6B

Total deal value

Phase 1 CAR-T (Median)

$1.0B

Total deal value

Phase 3 Small Molecule

$3.1B

Total deal value

ADC Royalty Range

13.6%-22.2%

Base tier rates

Model Your Deal

Market Analysis

The 2026 oncology licensing market continues to be driven by innovation in antibody-drug conjugates, bispecific antibodies, radiopharmaceuticals, and cell therapies. Phase 2 ADC deals lead in total deal value at $2.6B median, while Phase 1 CAR-T transactions command $1.0B on the strength of clinical proof of concept in hematologic malignancies. Phase 3 small molecule deals average $3.1B with the highest upfront ratios.

Deal structures across oncology modalities share common patterns but diverge in key areas. ADC and bispecific deals are characterized by higher development milestone allocations due to manufacturing and formulation complexity. CAR-T and gene therapy deals feature longer milestone schedules reflecting extended development timelines. Small molecules and naked antibodies follow more traditional milestone structures.

Royalty rates in oncology licensing have stabilized in the 13.6%-22.2% range at the base tier for most modalities, with tiered escalation rewarding blockbuster commercial performance. The most competitive pressure on royalty rates comes from crowded IO-combination and kinase inhibitor spaces, while novel modalities with limited competition command premium rates.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are the highest-value oncology deal modalities in 2026?

ADCs, radiopharmaceuticals, and CAR-T cell therapies command the highest total deal values in oncology. Phase 2 ADC deals average $2.6B, while Phase 1 CAR-T deals reach $1.0B, reflecting the transformative clinical potential and manufacturing barriers of these modalities.

How do oncology deal terms vary by clinical stage?

Oncology deal values increase significantly with clinical de-risking. Phase 3 assets command approximately $3.1B with $702M upfronts, while preclinical assets trade at substantially lower multiples. The optimal licensing window for most oncology assets is Phase 2 after proof-of-concept data.

What oncology indications command the highest deal values?

NSCLC, breast cancer (particularly TNBC), and multiple myeloma are the most actively transacted oncology indications. NSCLC commands premium valuations due to market size, while rare cancers (cholangiocarcinoma, mesothelioma) can achieve high deal values through orphan drug pathways and limited competition.

What trends are shaping oncology licensing in 2026?

Key trends include the continued ADC premium driven by next-generation payloads and targets, growing demand for radiopharmaceutical assets, increased deal activity in bispecific platforms, and the emergence of bispecific-ADC and combination IO approaches. Biomarker-selected strategies continue to drive premium valuations across all modalities.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Oncology Licensing Deal Benchmarks 2026

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

ADC Deal Benchmarks

CAR-T Cell Therapy Deals

Bispecific Antibody Deals

Neurology & CNS Deals

Ready to Calculate Your Deal Terms?